Warning! GuruFocus detected
1 Severe warning sign
with MTVA.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
MetaVia Inc (NAS:MTVA) Stock News, Headlines & Updates
MetaVia Inc Stock News from GuruFocus
- 1
Apr 23, 2025
MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025
PRNewswire • 8:00am
MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025 | MTVA Stock News
GuruFocus News • 7:47am
Apr 22, 2025
MetaVia (MTVA) Advances DA-1726 in Obesity Treatment with Promising Phase 1 Results | MTVA Stock News
GuruFocus News • 8:16am
MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstra
GuruFocus News • 7:46am
Apr 15, 2025
MetaVia (MTVA) Reports Promising Phase 1 Trial Results for Obesity Drug DA-1726 | MTVA Stock News
GuruFocus News • 6:22am
MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safet
GuruFocus News • 6:18am
Mar 22, 2025
MetaVia Inc (MTVA) Reports Q4 EPS of -0.59, Revenue at $0 Million
GuruFocus News • 3:30am
Mar 20, 2025
MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update
PRNewswire • 7:00am
Feb 15, 2025
ARMISTICE CAPITAL, LLC Increases Stake in MetaVia Inc
GuruFocus News • 4:47am
- 1
Show
Entries
Headlines
Total 0- 1
No recent news